{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:02:19Z","timestamp":1784628139986,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13300-026-01885-1","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T09:31:00Z","timestamp":1780133460000},"page":"1015-1026","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Change in Effectiveness and Safety Parameters After Initiation of SGLT2 Inhibitors for Post-Transplant Diabetes Mellitus: A Real-World Observational Study"],"prefix":"10.1007","volume":"17","author":[{"given":"Maria Cristina","family":"Crepaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Vedovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Luca","family":"Morieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Federica","family":"Stefanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fioretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-2097","authenticated-orcid":false,"given":"Gian Paolo","family":"Fadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"3","key":"1885_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/ndt\/gfv368","volume":"31","author":"EL Porrini","year":"2016","unstructured":"Porrini EL, Diaz JM, Moreso F, et al. Clinical evolution of post-transplant diabetes mellitus. Nephrol Dial Transpl. 2016;31(3):495\u2013505.","journal-title":"Nephrol Dial Transpl"},{"issue":"9","key":"1885_CR2","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1111\/ajt.12850","volume":"14","author":"A Sharif","year":"2014","unstructured":"Sharif A, Hecking M, de Vries AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014;14(9):1992\u20132000.","journal-title":"Am J Transplant"},{"issue":"1","key":"1885_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1210\/er.2015-1084","volume":"37","author":"V Shivaswamy","year":"2016","unstructured":"Shivaswamy V, Boerner B, Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev. 2016;37(1):37\u201361.","journal-title":"Endocr Rev"},{"issue":"6","key":"1885_CR4","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1111\/j.1523-1755.2005.00349.x","volume":"67","author":"FG Cosio","year":"2005","unstructured":"Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005;67(6):2415\u201321.","journal-title":"Kidney Int"},{"issue":"6","key":"1885_CR5","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1253\/circj.CJ-16-0963","volume":"81","author":"HJ Kim","year":"2017","unstructured":"Kim HJ, Jung SH, Kim JJ, et al. New-onset diabetes mellitus after heart transplantation\u2013incidence, risk factors and impact on clinical outcome. Circ J. 2017;81(6):806\u201314.","journal-title":"Circ J"},{"issue":"2","key":"1885_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s13300-018-0374-8","volume":"9","author":"MJ Pelaez-Jaramillo","year":"2018","unstructured":"Pelaez-Jaramillo MJ, Cardenas-Mojica AA, Gaete PV, Mendivil CO. Post-liver transplantation diabetes mellitus: a review of relevance and approach to treatment. Diabetes Ther. 2018;9(2):521\u201343.","journal-title":"Diabetes Ther"},{"issue":"3","key":"1885_CR7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/ndt\/gfs583","volume":"28","author":"M Hecking","year":"2013","unstructured":"Hecking M, Werzowa J, Haidinger M, et al. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Trans. 2013;28(3):550\u201366.","journal-title":"Nephrol Dial Trans"},{"issue":"15","key":"1885_CR8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"7","key":"1885_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type\u00a02 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"1885_CR10","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type\u00a02 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"10","key":"1885_CR11","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1016\/j.transproceed.2019.05.023","volume":"51","author":"N Attallah","year":"2019","unstructured":"Attallah N, Yassine L. Use of empagliflozin in recipients of kidney transplant: a report of 8 cases. Transplant Proc. 2019;51(10):3275\u201380.","journal-title":"Transplant Proc"},{"issue":"6","key":"1885_CR12","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2337\/dc19-0093","volume":"42","author":"TAS Halden","year":"2019","unstructured":"Halden TAS, Kvitne KE, Midtvedt K, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care. 2019;42(6):1067\u201374.","journal-title":"Diabetes Care"},{"issue":"6","key":"1885_CR13","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/ckj\/sfad007","volume":"16","author":"AI Sanchez Fructuoso","year":"2023","unstructured":"Sanchez Fructuoso AI, Bedia Raba A, et al. Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type\u00a02 or post-transplant diabetes: an observational multicentre study. Clin Kidney J. 2023;16(6):1022\u201334.","journal-title":"Clin Kidney J"},{"issue":"1 Suppl 1","key":"1885_CR14","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in Diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S27\u201349.","journal-title":"Diabetes Care"},{"issue":"5","key":"1885_CR15","doi-asserted-by":"publisher","first-page":"392","DOI":"10.7861\/clinmed.2019-0195","volume":"19","author":"TA Chowdhury","year":"2019","unstructured":"Chowdhury TA. Post-transplant diabetes mellitus. Clin Med. 2019;19(5):392\u20135.","journal-title":"Clin Med"},{"issue":"9","key":"1885_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1885_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"24","key":"1885_CR18","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1885_CR19","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","DOI":"10.1056\/NEJMoa2204233"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01885-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01885-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01885-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:07:47Z","timestamp":1784624867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01885-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1885"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01885-1","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mario Luca Morieri received honoraria or speaker fees from Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Guidotti, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi, and Servier. Paola Fioretto received fees as consultant and speaker for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. Gian Paolo Fadini received honoraria for consultancy, advisory boards or lectures from AstraZeneca, Boehringer, Lilly, Novartis, Novo Nordisk, Sanofi. Maria Cristina Crepaldi, Monica Vedovato, Giovanni Basso, Lucia Federica Stefanelli, and Marianna Alessi have nothing to disclose. Gian Paolo Fadini is an Editorial Board member of\n                      Diabetes Therapy\n                      . Gian Paolo Fadini was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of The University Hospital of Padova (CET ACEV, prot 422n\/AO\/2) and conducted in accordance with the Helsinki Declaration of 1964, and its later amendments. All participants signed written informed consent. Patients signed written informed consent for their data to be used in the protocol referred to in the text, which covers the analysis presented in the manuscript.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}